BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ACI-24.060 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ACI-24.060\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05462106-680@assetmemo.bio
DTSTAMP:20261121T010136Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:ACI-24.060: Phase 1/2 readout est. (NCT05462106)
DESCRIPTION:ACI-24.060\, phase 1/2\, Alzheimer's Disease.\nStudy: A Study t
 o Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Synd
 rome (ABATE Study)\nEstimated primary completion: April 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/aci-24-060#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05462106
URL:https://assetmemo.bio/drug/aci-24-060#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
